Angal Biotechnology

JLP Health and Angalbio envision to develop first-in-class treatment opportunities in the areas of cancer and life-threatening diseases based on novel drug target structures emerging from mode of action studies of natural compounds.

Angalbio was established in June 2019 in Suzhou High Tech Zone as a Joint Venture of JLP Health GmbH, holding 90% of the shares, with Jiangsu Provincial Industrial Technology Research Institute (JITRI) and Suzhou New High Tech District (SND), each of which holding 5% of the shares.


Angalbio combines the power of Western technology with the secrets of 3000 years of medical tradition in China to find new drug targets.
 

Angalbio offers target deconvolution services through forward genetics to mainland China.